Poolbeg Pharma has announced that the European Patent Office has granted Poolbeg’s European Immunomodulator II patent application covering POLB 001 for the treatment of severe influenza.
POLB 001 is a potent and selective p38 MAP kinase inhibitor with strong potential across multiple disease areas.
These include the prevention and treatment of cancer immunotherapy-induced Cytokine Release Syndrome ("CRS"), a potential market opportunity of more than $10bn and the treatment of severe influenza.
The drug holds the potential to address significant unmet needs affecting patients and healthcare systems globally.
Poolbeg Pharma is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field.
Poolbeg is actively building a comprehensive, worldwide IP portfolio, with patents covering the use of p38 MAPK inhibitors in patients with severe influenza and for the prevention and treatment of cancer immunotherapy-induced CRS.
This patent grant further strengthens the company's robust intellectual property portfolio, enhancing POLB 001's value and appeal to potential partners.
Dr Jeremy Skillington, CEO of Poolbeg Pharma, said: “This patent grant from the European Patent Office highlights the strong progress we continue to make in developing and strengthening our IP portfolio for POLB 001 across multiple disease indications."
"This further enhances the value and attractiveness of POLB 001 for potential partners.”